Bliss GVS Pharma Share Price

Bliss GVS Pharma

CMP as on 19-May-22 15:30

₹ 71.25
-1.80 -2.46%

Open

₹ 71.45

Turnover (lac)

₹ 39

Prev. Close

₹ 73.05

Day's Vol (shares)

₹ 54,881

Day's Range (₹)

₹ 68.20
₹ 72.40

CMP as on19-May-22 15:29

₹ 71.10
-2.05 -2.8%

Open

₹ 70.50

Turnover (lac)

₹ 22

Prev. Close

₹ 73.15

Day's Vol (shares)

₹ 12,629

Day's Range

₹ 70.00
₹ 72.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 22-Apr-2022 - -
Final Dividend & Audited Results Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company will be held on April 30, 2022, inter alia, to transact the following: 1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2022, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of Audit Report with modified opinion, if any, thereon. 2. To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2022 and 3. To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2022. 1.The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2022 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2022 3. Re-appointment of M/s. Kalyaniwalla Mistry & LLP, Chartered Accountants (Firm Registration No. 104607W/W100166), Peer Reviewed Firm as the Statutory Auditors 4. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2022-23 5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries, Peer Reviewed Firm as Secretarial Auditor of the Company for the financial year 2022-23 6. 37th AGM of the Company for the Financial Year 2021-2022 has been scheduled to be held on Tuesday, June 28, 2022 at 11:00 a.m. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) facility (As Per BSE Announcement Dated on 02.05.2022)
Board Meeting - 21-Jan-2022 - -
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2021. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from January 01 2022 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2021. This intimation is also being uploaded on the Companys website at http://www.blissgvs.com/. Kindly acknowledge and take on record the same. We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, January 29, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as Annexure - I. (As Per BSE Announcement Dated on 29/01/2022)
Board Meeting - 22-Oct-2021 - -
Quarterly Results We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, October 30, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment. (As Per BSE Announcement Dated on 30/10/2021)
Board Meeting - 23-Jul-2021 - -
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Saturday, July 31, 2021 at the registered office of the Company to consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Companys Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01, 2021 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2021. We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, July 31, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment. (As per BSE Announcement Dated on 31/07/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity